The significance of IL-19 in the liver: crosstalk among inflammation, metabolism, and fibrosis

Cell Type–Dependent Pro- and Anti-Inflammatory Role of Signal Transducer and Activator of Transcription 3 in Alcoholic Liver Injury

This Month in Gastroenterology

Annual Burden and Costs of Hospitalization for High-Need, High-Cost Patients With Chronic Gastrointestinal and Liver Diseases

Macrophage heterogeneity in liver injury and fibrosis

Alcoholic Liver Disease: Pathogenesis and New Therapeutic Targets

Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic.

Lipids in Liver Disease: Looking Beyond Steatosis

Shedding new light on vitamin D and fatty liver disease

The Negative Bidirectional Interaction Between Climate Change and the Prevalence and Care of Liver Disease: A Joint BSG, BASL, EASL, and AASLD Commentary

The Impact of Liver Disease on Growth and Nutrition

Answer questions and earn CME Hemochromatosis is the group of disorders caused by systemic iron overload. These can be inherited (hereditary hemochromatosis [HH]) or secondary to a number of conditions, such as multiple blood transfusions, dyserythropoiesis, and chronic liver disease. The liver is commonly affected, and in severe cases, these disorders can lead to cirrhosis and hepatocellular carcinoma (HCC). This review will cover the histological pattern of hepatic iron overload and its diagnostic and therapeutic implications. HH is one of the most common inherited disorders in individuals of northern European descent and is defined as pathological iron overload caused by hepcidin deficiency.1, 2 Because the human body has no physiological mechanism to excrete excess iron, iron homeostasis depends on the regulation of duodenal absorption of dietary iron and cycling of erythrocyte iron by macrophages (Fig. 1).2 In HH, a variety of genetic defects ultimately results in hepcidin deficiency and subsequent increase in iron stores in the body. Four major HH categories have been described (Table 1). Type 1 HH is the most frequent genetic iron overload disease and is caused by mutations in the HFE gene. Homozygous C282Y mutation is classified as type 1a, whereas compound C282Y and H63D mutations are classified as type 1b. Type 2 HH or juvenile hemochromatosis is caused by defects in the hemojuvelin (HJV) gene or hepcidin (HAMP [hepatic antimicrobial protein]) gene, and is the most severe form of systemic iron overload, presenting at an earlier age than the other HH types. Type 3 HH is linked to mutations in the transferrin receptor 2 (TFR2). Type 4 HH is caused by defects in the ferroportin 1 (FPN or SLC4A1) gene and is the only HH category with increased hepcidin.2, 3 Most HH patients are asymptomatic because the disease tends to manifest late in its course. Clinical features of iron accumulation are not limited to the liver and include cardiomyopathy, arthropathy, skin hyperpigmentation, diabetes, and hypogonadism. Laboratory studies show increased transferrin saturation and elevated ferritin levels. The liver is most commonly affected in type 1 HH, and progression to cirrhosis can occur in as much as 10% of untreated patients, particularly in individuals with very high serum ferritin levels (>1000 ng/mL).4 Secondary iron overload can occur in a variety of conditions (Table 2), including anemias with ineffective erythropoiesis, blood transfusions, hemodialysis, and anemia of chronic disease. Significant hepatic iron overload can also occur in the setting of chronic liver disease, including alcoholic and nonalcoholic fatty liver disease (NAFLD), chronic viral hepatitis, porphyria cutanea tarda, and cirrhosis. In fact, stainable iron is a fairly common finding in cirrhosis of any cause.5 The mechanisms by which chronic liver disease leads to iron accumulation are only partially elucidated. In the setting of alcohol abuse, for instance, metabolism of excess ethanol results in downregulation of hepcidin expression leading to increased intestinal iron absorption and elevated serum ferritin.6 In patients with NAFLD, insulin resistance appears to play a role in decreased hepcidin levels, causing the so-called dysmetabolic hepatic iron overload syndrome.7 When untreated, severe cases of secondary iron overload can result in the same complications seen in HH. Even though the use of magnetic resonance imaging has reduced the need for liver biopsies to diagnose and grade hepatic iron overload, liver biopsy remains the preferred method to stage hepatic fibrosis and/or evaluate for other liver disease causative factors.4 This is particularly important because advanced fibrosis is associated with higher risk for HCC and increased mortality. In fact, it has been shown that severe liver fibrosis can regress with therapy, and significant fibrosis regression is associated with significant reduction in long-term risk for HCC.8 Because HH can be occult in the initial phase of disease, liver biopsy sometimes allows for the early identification of patients with HH. Histological evaluation of the liver can also identify underlying or superimposed conditions and help guide clinical management. The histological pattern of hepatic iron overload is determined according to the cellular compartment where iron accumulates and correlates with the disease etiology. Liver cells (hepatocytes and Kupffer cells) store iron in the form of ferritin, heme, and lysosomal hemosiderin, the latter being the predominant form of stainable iron.9 On routine hematoxylin and eosin stains, hemosiderin deposits are golden-brown refractile granules. Because small amounts of iron can be difficult to visualize, histochemical stains are typically done. The most commonly used method, the Perls' Prussian blue stain, highlights hemosiderin granules in blue (Fig. 2). Because normal liver is negative for stainable iron, any positive staining requires mention and interpretation by the pathologist. Two main patterns of iron accumulation have been described: parenchymal iron overload and Kupffer cell hemosiderosis. Parenchymal iron accumulation is the pattern seen in inherited forms of iron overload (also known as primary iron overload) and is characterized by iron accumulation in hepatocytes and bile duct epithelium. In hepatocytes, hemosiderin initially accumulates in a pericanalicular distribution. In the lobules, hepatocellular iron buildup is zonal and first affects periportal (zone 1) hepatocytes, extending toward zones 2 and 3 as iron overload progresses. This results in a gradient of staining from the periphery of the lobules toward the central veins (Fig. 2E,F). Many different grading systems are available for subjective quantification of parenchymal iron. The grading system described by Scheuer, for instance, scores hepatocellular iron on a scale of 1 to 4, ranging from minimal iron accumulation (grade 1) to diffuse accumulation that involves the entire lobule and obliterates the typical gradient (grade 4).10 In more severe cases, iron can be found in bile duct epithelial cells and may also extend to the Kupffer cells and portal macrophages (Fig. 3C). In advanced cases, portal fibrosis and eventually cirrhosis develop with an increased risk for HCC (Fig. 3E,F). This pattern of iron accumulation is characteristic of HH and in the absence of underlying liver disease, it should be followed up with serum iron studies and HFE gene testing. Kupffer cell hemosiderosis, or secondary iron overload pattern, refers to hemosiderin accumulation in Kupffer cells, and sometimes portal macrophages and endothelial cells (Fig. 2C,D).11 This pattern is seen in a number of conditions summarized in Table 2. It can also be seen after hepatocellular injury (e.g., acute hepatitis) because of the increased turnover of injured hepatocytes leading to transient Kupffer cell hemosiderosis. This pattern is also described in HH type 4 (FPN disease). Even though no formal grading system exists for Kupffer cell hemosiderosis, it can be generally categorized as focal (when it involves sparse Kupffer cells) and diffuse (when most Kupffer cells show stainable iron) (Fig. 4). Mixed patterns of iron accumulation are not uncommon and can be challenging to interpret. They typically occur in cases of severe iron overload, chronic liver disease, and multifactorial conditions (Figs. 2D and 4B). In addition to stainable iron and fibrosis, liver tissue can be used to determine the hepatic iron concentration (HIC). HIC results can help confirm genetic iron overload in patients who lack the most common gene mutations.4 In addition, it is used to assess the need for iron chelation therapy in patients with secondary overload, in whom serum ferritin levels may not correlate with the degree of hepatic iron deposition.4, 12, 13 HIC can be determined by colorimetry or atomic absorption. Accurate HIC measurements require adequate liver samples with >1 mg dry weight. This test can be accomplished using fresh or formalin-fixed tissue. However, since iron accumulation can be heterogeneous in the liver, fixed tissue is preferred because it allows the pathologist to assure the specimen quality (i.e., mostly parenchyma, avoiding scar or capsular areas).14, 15 The hepatic iron index (HII) is calculated from the HIC and can be useful in early/mild cases of iron overload. It accounts for the fact that iron stores accumulate progressively over time and is calculated by dividing the HIC in μmol/g dry weight by the patient's age in years. The normal range for HII is less than 1.0.15 In summary, hepatic iron overload can be primary, as a result of genetic defects in iron regulatory proteins, or secondary, as a result of increased erythrocyte turnover/hemolysis, systemic diseases, and chronic liver disease. Histological evaluation of the liver is used to establish the predominant pattern of iron accumulation, the degree of iron overload, and the fibrosis stage. This information can ultimately inform the causative factor of iron overload and guide the need for phlebotomy, chelation therapy, and cancer surveillance in patients with cirrhosis.

Mo1254 Reduction in Colectomy- and Health Care-Related Costs in Ulcerative Colitis Patients Treated With Adalimumab Compared With Standard Therapy

The BH3-Only Protein Bid Does Not Mediate Death-Receptor-Induced Liver Injury in Obstructive Cholestasis

HE liver plays a key role in the synthesis of proteins, metabolism of toxins and drugs, and in modulation of immunity. In critically ill patients, hypoxic, toxic, and inflammatory insults can affect hepatic excretory, synthetic, and/or purification functions, leading to systemic complications such as coagulopathy, increased risk of infection, hypoglycemia, and acute kidney injury. In severe cases, hepatic encephalopathyorbraindysfunction(acuteliverfailure)may occur. Because of the lack of specificity of standard laboratory investigations, identifying liver injury or dysfunction in critically ill patients remains a significant challenge. In addition, the great heterogeneity of criteria used to define the consequences of liver insults increases the difficulties for the clinician to properly interpret hepatic biochemical abnormalities. In this review, we choose to defineliver injuryas an elevation in serum concentrations of routinely measured hepatic enzymes, including aminotransferases (aspartate aminotransferase [AST]; alanine aminotransferase, [ALT]), alkaline phosphatase (ALP), or!-glutamyl transpeptidase. Hepatic dysfunctionrefers to derangement of pathways related to synthetic or clearance function, including international normalized ratio (INR) and bilirubin.Hepatotoxicity refers to hepatic injury and dysfunction caused by a drug or another noninfectious agent. 1 Acute liver failuredesignates

The role of the gut microbiome in chronic liver disease: the clinical evidence revised.